Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.
No Thumbnail Available
Authors
Othman J.
Potter N.
Freeman S.D.
McCarthy N.
Jovanovic J.
Runglall M.
Canham J.
Thomas I.
Johnson S.
Gilkes A.
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
We analyzed 217 patients with KMT2A-rearranged acute myeloid leukemia (AML) in 2 large sequential randomized trials. Those randomized to FLAG-Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubucin) had markedly lower rates of relapse than other chemotherapy regimens. Molecular measurable residual disease assessment after cycle 2 was strongly prognostic for relapse and death. The trials were registered at the ISRCTN Registry as AML17 ISRCTN55675535 and AML19 ISRCTN78449203. Copyright © 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Description
Citation
Publisher
License
Journal
Blood
Volume
146
Issue
10